|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2006-5-18
|
|
pubmed:abstractText |
The incidence of melanoma is rising, and therapeutic options for metastatic melanoma are limited. We report the results of experimental melanoma therapy with 188-Rhenium-labeled melanin-binding decapeptide ((188)RE-HYNIC-4B4) and a comprehensive safety evaluation of this treatment. (188)RE-HYNIC- 4B4 bound only to nonviable eumelanotic MNT1 and pheomelanotic SK-28-MEL human melanoma cells in vitro, as determined by immunofluorescence, which is consistent with the inaccessibility of intracellular melanin in live cells, and suggests specificity for tumors with a significant amount of extracellular melanin. Administration of 1 mCi (188)RE-HYNIC-4B4 to MNT1 tumor-bearing mice significantly slowed tumor growth, with the therapeutic effect being a result of specific binding to tumor melanin, as irrelevant (188)RE-labeled decapeptide did not produce therapeutic gain. Repeated doses of (188)RE-HYNIC-4B4 had a more profound effect on tumor growth than a single dose. Treatment of tumors with 0.3-0.4 cm diameter was more effective than of larger ones (0.5-0.7 cm). There was no difference in uptake of (188)REHYNIC- 4B4 in melanized tissues of black C57BL6 mice and no histologically apparent damage to these tissues in comparison with white BALB/C mice. Treatment of C57BL6 mice with (188)RE-HYNIC-4B4 did not change their behavior, as established by SHIRPA protocol, and did not cause damage to neurons and glial cells. These results indicate that radiolabeled melanin-binding peptides are efficient and safe in treatment of melanoma and could be potentially useful against this tumor.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1084-9785
|
|
pubmed:author |
pubmed-author:BryanRuth ARA,
pubmed-author:CasadevallArturoA,
pubmed-author:DadachovaEkaterinaE,
pubmed-author:HuangXianchuanX,
pubmed-author:MintsLisaL,
pubmed-author:MoadelTiffanyT,
pubmed-author:NosanchukJerome SJS,
pubmed-author:NosanchukJoshua DJD,
pubmed-author:OrtizGeraldinaG,
pubmed-author:RevskayaEkaterinaE,
pubmed-author:SchweitzerAndrew DAD,
pubmed-author:ZhangTongT
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
117-29
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:16706632-Animals,
pubmed-meshheading:16706632-Brain Diseases,
pubmed-meshheading:16706632-Cell Line, Tumor,
pubmed-meshheading:16706632-Chromatography, High Pressure Liquid,
pubmed-meshheading:16706632-Female,
pubmed-meshheading:16706632-Fluorescent Antibody Technique,
pubmed-meshheading:16706632-Humans,
pubmed-meshheading:16706632-Hydrazines,
pubmed-meshheading:16706632-Immunotoxins,
pubmed-meshheading:16706632-Kidney Diseases,
pubmed-meshheading:16706632-Male,
pubmed-meshheading:16706632-Melanins,
pubmed-meshheading:16706632-Melanoma,
pubmed-meshheading:16706632-Mice,
pubmed-meshheading:16706632-Mice, Inbred BALB C,
pubmed-meshheading:16706632-Mice, Inbred C57BL,
pubmed-meshheading:16706632-Mice, Nude,
pubmed-meshheading:16706632-Nicotinic Acids,
pubmed-meshheading:16706632-Peptides,
pubmed-meshheading:16706632-Radioimmunotherapy,
pubmed-meshheading:16706632-Radioisotopes,
pubmed-meshheading:16706632-Radiopharmaceuticals,
pubmed-meshheading:16706632-Rhenium,
pubmed-meshheading:16706632-Tissue Distribution,
pubmed-meshheading:16706632-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Radiolabeled melanin-binding peptides are safe and effective in treatment of human pigmented melanoma in a mouse model of disease.
|
|
pubmed:affiliation |
Department of Nuclear Medicine, Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10461, USA. edadacho@aecom.yu.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
